Mohammad Amin Ghanbari1, Taghi Lashkar Bolouki1, Pirasteh Norouzi2, Fatemeh Sadat Bitaraf3, Haniye Bakhshi4, Amir Atashi5. 1. School of Biology, Damghan University, Damghan, Iran. 2. School of Medicine, Shahroud University of Medical Sciences, Shahroud, Iran. 3. Department of Medical Biotechnology, School of Medicine, Shahroud University of Medical Sciences, Shahroud, Iran. 4. Department of Hematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran. 5. Stem Cell and Tissue Engineering Research Center, Shahroud University of Medical Sciences, Shahroud, Iran.
Abstract
Background: Sepsis is one of the main concerns of health and one of the leading causes of death in hospitals. It is essential to manage sepsis in hospitalized patients. In recent years, cell therapy has been considered as a new approach to treat sepsis. This study evaluated the effect of CXCR4 as one of the main proteins involved in the homing of mesenchymal stem cells in the sepsis serum in mice model. Methods: Mouse sepsis model was induced by injection of E.coli and biochemical analyses was done to confirm the organ failure. Mesenchymal stem cells (MSCs) derived from bone marrow were separated into sepsis and control groups. In the sepsis serum group, MSCs were treated with sepsis serum at two time points: 24 and 48 h. Quantitative RT-PCR and flow cytometry were performed to determine the mRNA expression of CXCR4 in sepsis serum group compared to control group. Also, a migration assay was done to assess the migration capacity of bone marrow MSCs during inflammation and treatment in sepsis. Results: Our result showed that treatment with sepsis serum can control migration by decrease in CXCR4 level (P ≤ 0.05) compared to control group. Moreover it was also reported that sepsis serum decreased mRNA expression of CXCR4 in MScs. Conclusions: In our study, MSCs treated with septic serum were no longer able to migrate . Probably many variables such as source, dose, injection time, and injection route of MSCs after sepsis induction in the animal models are key factors for successful cell therapy.
Background: Sepsis is one of the main concerns of health and one of the leading causes of death in hospitals. It is essential to manage sepsis in hospitalized patients. In recent years, cell therapy has been considered as a new approach to treat sepsis. This study evaluated the effect of CXCR4 as one of the main proteins involved in the homing of mesenchymal stem cells in the sepsis serum in mice model. Methods: Mouse sepsis model was induced by injection of E.coli and biochemical analyses was done to confirm the organ failure. Mesenchymal stem cells (MSCs) derived from bone marrow were separated into sepsis and control groups. In the sepsis serum group, MSCs were treated with sepsis serum at two time points: 24 and 48 h. Quantitative RT-PCR and flow cytometry were performed to determine the mRNA expression of CXCR4 in sepsis serum group compared to control group. Also, a migration assay was done to assess the migration capacity of bone marrow MSCs during inflammation and treatment in sepsis. Results: Our result showed that treatment with sepsis serum can control migration by decrease in CXCR4 level (P ≤ 0.05) compared to control group. Moreover it was also reported that sepsis serum decreased mRNA expression of CXCR4 in MScs. Conclusions: In our study, MSCs treated with septic serum were no longer able to migrate . Probably many variables such as source, dose, injection time, and injection route of MSCs after sepsis induction in the animal models are key factors for successful cell therapy.
Authors: Rosemarijn Renckens; Joris J T H Roelofs; Sandrine Florquin; Alex F de Vos; Jennie M Pater; H Roger Lijnen; Peter Carmeliet; Cornelis van 't Veer; Tom van der Poll Journal: J Immunol Date: 2006-07-15 Impact factor: 5.422
Authors: Manoj M Lalu; Katrina J Sullivan; Shirley Hj Mei; David Moher; Alexander Straus; Dean A Fergusson; Duncan J Stewart; Mazen Jazi; Malcolm MacLeod; Brent Winston; John Marshall; Brian Hutton; Keith R Walley; Lauralyn McIntyre Journal: Elife Date: 2016-11-17 Impact factor: 8.140